Cite
HARVARD Citation
Yin, M. et al. (2022). STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway. Cell cycle. 21 (8), pp. 767-779. [Online].